Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by on Jun 11th, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $143.8333.

A number of analysts have commented on DRUG shares. BTIG Research reaffirmed a “buy” rating and set a $147.00 target price on shares of Bright Minds Biosciences in a report on Monday, March 30th. HC Wainwright reaffirmed a “buy” rating and set a $145.00 target price on shares of Bright Minds Biosciences in a report on Monday, June 1st. Piper Sandler reaffirmed an “overweight” rating and set a $220.00 target price (up from $190.00) on shares of Bright Minds Biosciences in a report on Wednesday, May 20th. Jefferies Financial Group began coverage on shares of Bright Minds Biosciences in a report on Monday, April 13th. They issued a “buy” rating and a $145.00 price target for the company. Finally, Robert W. Baird set a $126.00 price target on shares of Bright Minds Biosciences in a report on Friday, February 13th.

Check Out Our Latest Report on DRUG

Insider Activity

In other news, major shareholder Cormorant Asset Management, Lp sold 109,331 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $89.50, for a total value of $9,785,124.50. Following the completion of the transaction, the insider owned 950,000 shares of the company’s stock, valued at $85,025,000. The trade was a 10.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 42.66% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bright Minds Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in DRUG. Braidwell LP bought a new stake in Bright Minds Biosciences during the 3rd quarter worth about $18,422,000. Seven Grand Managers LLC bought a new stake in Bright Minds Biosciences during the 4th quarter worth about $3,902,000. Gordian Capital Singapore Pte Ltd bought a new stake in Bright Minds Biosciences during the 3rd quarter worth about $73,000. Royal Bank of Canada lifted its position in Bright Minds Biosciences by 240.0% during the 4th quarter. Royal Bank of Canada now owns 527 shares of the company’s stock worth $40,000 after buying an additional 372 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Bright Minds Biosciences by 32.7% during the 1st quarter. Bank of New York Mellon Corp now owns 13,253 shares of the company’s stock worth $967,000 after buying an additional 3,264 shares in the last quarter. Institutional investors and hedge funds own 40.52% of the company’s stock.

Bright Minds Biosciences Stock Performance

DRUG opened at $61.56 on Thursday. The company has a fifty day moving average price of $82.03 and a two-hundred day moving average price of $80.54. Bright Minds Biosciences has a 52 week low of $23.17 and a 52 week high of $123.75. The firm has a market capitalization of $598.98 million, a PE ratio of -25.23 and a beta of -5.53.

Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last released its earnings results on Wednesday, May 20th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.06. Equities analysts forecast that Bright Minds Biosciences will post -4.9 EPS for the current year.

Bright Minds Biosciences Company Profile

(Get Free Report)

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.

Featured Stories

Analyst Recommendations for Bright Minds Biosciences (NASDAQ:DRUG)

Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.